NASDAQ: CLRBCellectar Biosciences Inc Stock Ownership - Who owns Cellectar Biosciences?
Insider buying vs selling
Have Cellectar Biosciences Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| James V. Caruso | Chief Executive Officer | 2026-05-07 | 8,680 | $2.88 | $25.00kBuy |
| Jarrod Longcor | Chief Operating Officer | 2026-05-07 | 8,680 | $2.88 | $25.00kBuy |
| John Neis | Director | 2025-12-12 | 198 | $3.70 | $732.01Sell |
CLRB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CLRB insiders and whales buy or sell their stock.
CLRB Shareholders
What type of owners hold Cellectar Biosciences Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Austin W. Greenhouse David M. Marxe | 12.09% | 1,142,368 | $1.38M | Insider |
| Cormorant Asset Management LP | 5.61% | 530,000 | $638.65k | Insider |
| Alumni Research Foundation Wisconsin | 4.97% | 469,484 | $565.73k | Insider |
| John Neis | 3.85% | 363,725 | $438.29k | Insider |
| Richard Hertzberg | 2.96% | 280,000 | $337.40k | Insider |
| Jamey P. Weichert | 2.49% | 235,336 | $283.58k | Insider |
| Paul L. Berns | 1.24% | 117,371 | $141.43k | Insider |
| Andrei Shustov | 0.58% | 55,037 | $66.32k | Insider |
| Darrell Shane Lea | 0.42% | 39,599 | $47.72k | Insider |
| Douglas J. Swirsky | 0.26% | 25,000 | $30.13k | Insider |
CLRB vs Biotech Stocks
Cellectar Biosciences Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.